BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2058083)

  • 61. Classification of myeloproliferative disorders by bone marrow histology.
    Frisch B; Bartl R; Burkhardt R; Jäger K; Mahl G; Kettner G
    Bibl Haematol; 1984; (50):57-80. PubMed ID: 6590039
    [No Abstract]   [Full Text] [Related]  

  • 62. Circulating erythroid and megakaryocytic progenitors in polycythaemia vera and essential thrombocythaemia.
    Florensa L; Besses C; Almarcha J; Lafuente R; Palou L; Pedro C; Sans-Sabrafen J; Woessner S
    Eur J Haematol; 1989 Nov; 43(5):417-22. PubMed ID: 2693129
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enzyme negative blastic transformation of chronic myeloproliferative disorders: immunophenotyping of the blastic cell population.
    Matolcsy A; Izer I; Magyarlaki T; Baranyay F
    Haematologia (Budap); 1991; 24(1):27-37. PubMed ID: 1813360
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bone marrow stromal cells in myeloproliferative disorders.
    Hirata J; Takahira H; Kaneko S; Nishimura J; Nawata H
    Acta Haematol; 1989; 82(1):35-9. PubMed ID: 2505472
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pathologic study on megakaryocytes in chronic myeloproliferative disorders].
    Lin N; Liang P
    Zhonghua Bing Li Xue Za Zhi; 1991 Jun; 20(2):113-5. PubMed ID: 1914016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
    Frisch B; Bartl R; Burkhardt R; Jäger K
    Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Osteoclasts and bone remodeling in chronic myeloproliferative disorders. A histochemical and morphometric study on trephine biopsies in 165 patients.
    Thiele J; Hoeppner B; Wienhold S; Schneider G; Fischer R; Zankovich R
    Pathol Res Pract; 1989 Jun; 184(6):591-9. PubMed ID: 2780431
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
    Haferlach T; Kern W; Schnittger S; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders.
    Kawatani T; Endo A; Tajima F; Ooi S; Kawasaki H
    Int J Hematol; 1997 Feb; 65(2):123-8. PubMed ID: 9071816
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.
    Bock O; Hussein K; Neusch M; Schlué J; Wiese B; Kreipe H
    Eur J Haematol; 2006 Dec; 77(6):463-70. PubMed ID: 16930139
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
    Thiele J; Kvasnicka HM
    Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Megakaryocyte markers in myeloproliferative disorders.
    Iványi JL; Kiss A; Telek B; Tornai I
    Acta Histochem; 1993 Sep; 95(1):79-88. PubMed ID: 7506475
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The myeloproliferative disorders. An historical appraisal and personal experiences.
    Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
    Cashell AW; Buss DH
    Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human megakaryocytes. III. Characterization in myeloproliferative disorders.
    Rabellino EM; Levene RB; Nachman RL; Leung LL
    Blood; 1984 Mar; 63(3):615-22. PubMed ID: 6230121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.